Compounding Pharmacies for Weight-Loss Drugs Are Booming. Should You Trust Them?

Read the original at TIME ↗
TIME · collected 2026-10-07 · by Alana Semuels

Quick Summary

Diane Kinkade, 72, turned to a telehealth site and a compounding pharmacy after her doctor refused to prescribe her a GLP-1 weight-loss medication due to potential side effects. The compounding pharmacy provided her with tirzepatide at $250 per month, significantly cheaper than the brand-name drug Zepbound's cost of $399 through Eli Lilly’s direct-to-consumer site. However, Kinkade experienced severe side effects after a switch in pharmacies and ultimately stopped taking the medication due to poor telehealth support. Despite Eli Lilly asserting its monopoly on FDA-approved tirzepatide products until 2036, compounding pharmacies continue to supply compounded versions of the drug, with an estimated five million people using such medications in the U.S., according to a Gallup poll.
Written locally by qwen2.5:14b on 2026-10-07, using this article's own text rather than the other coverage of the same event (that is the story summary below).

AI analysis runs on qwen2.5:14b, locally

Story summary

In April 2026, the FDA clarified policies for compounding pharmacies, stating that if a compounded drug has the same active pharmaceutical ingredient as an existing brand-name drug and can be administered in the same way, it is considered essentially identical. This clarification impacted patients like Diane Kinkade, who sought weight-loss medication after traditional methods failed. Her doctor declined to prescribe GLP-1 drugs due to potential side effects, so she turned to a telehealth site that prescribed tirzepatide, the active ingredient in Eli Lilly’s drug Zepbound. The compounded form cost her only $250 per month, compared to $399 through LillyDirect. Despite initial weight loss success, Kinkade faced concerns when the telehealth service switched compounding pharmacies mid-treatment.

Written for “Weight Loss Drug Trend” on 2026-10-07, grounded in this article and the 0 other(s) covering the same event.

Signals How these are calculated →

Claims extracted
132
claim-shaped sentences
Uncertain
14%
19 of 132 hedged
Leaning
not political
takes no side on a contested political question
Correction & hedging signals
59.6
corrections and hedging in what we collected; not a measure of accuracy
Outlets on this story
1
Health
Narrative spread
1
articles carrying this framing
Analyzed 2026-10-07 · how these are computed

Story

📰 Weight Loss Drug Trend
Health · 1 article(s) covering the same event.

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Compared with similar articles

This article reads unscored and hedges 14% of its claims. Each row says how that neighbour differs.
New York Post
⚖️ leaning not scored 🔴 16% hedged 4 of 25 📰 publisher trust 64
“The articles discuss different topics within weight loss medication, one focusing on a new potential drug (CBL-514) and another discussing compounding pharmacies for GLP-1 drugs.”
Daily Mail
⚖️ Leans left 🔴 12% hedged 4 of 32 📰 publisher trust 65
“Article A discusses a crackdown on weight loss drug advertising by UK authorities, while Article B focuses on individual consumer experiences with compounding pharmacies for GLP-1 drugs.”
New York Post
⚖️ leaning not scored 🔴 8% hedged 2 of 25 📰 publisher trust 64
“Article A discusses the overall increase in GLP-1 medication use among US adults, while Article B focuses on an individual's experience with a compounding pharmacy for obtaining GLP-1 drugs.”

Publisher

TIME · 480 article(s) · 1 correction(s) detected
Running correction rate · 1 correction(s)
2026-09-17
Kerry James Marshall

Who wrote this

Alana Semuels
6 article(s) here · 1 carrying a prediction
🔮 The compounded drug represented significant cost savings—$250 a month versus the $399 a month she would have paid through LillyDirect, the direct-to-consumer site that people often use when their insurance doesn’t cover the drug.
🔮 “This rise in severe presentations might be a bit of a warning signal of a wider increase in harms across the general population,” says Ryan Forrest, a public-health doctoral student at the University of Toronto and one of the authors of the study.
2026-10-05 · assertive framing · Gambling Is Sending More People to the ER
🔮 As they got to know each other through the school’s international community—she’s from Brazil, he was raised in Lebanon—they eventually collaborated to found a company that would help popularize prediction markets, which had long been discussed in academic circles but never successfully marketed to the public.
2026-09-30 · mixed framing · Luana Lopes Lara and Tarek Mansour
🔮 The problem of insured Americans with medical debt could grow in the coming years as health insurance becomes less affordable.
🔮 That trait has served her well as chief operating officer of Kalshi, the New York-based prediction market that has boomed in recent years as people take up placing money on everything from what words the President will use in his speeches to the price of a Costco hot dog.
🔮 Dr. Elaine Batchlor, CEO of MLK Community Hospital in Los Angeles, already knows what will happen if her hospital closes.
Also by Alana Semuels
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 6 articles by Alana Semuels →

Topics

Eli Lilly FDA U.S. Zepbound a GLP-1 after

Subjects

FDA ORG · 5× U.S. GPE · 3× Eli Lilly ORG · 2× Kinkade PERSON · 2× Diane Kinkade PERSON · 1× Eli Lilly’s ORG · 1× LillyDirect ORG · 1× telehealth ORG · 1× the U.S. Food and Drug Administration ORG · 1× the United States GPE · 1×

Narrative

In April 2026, the FDA clarified policies for compounders, saying that a drug is essentially a copy if it has the same active pharmaceutical ingredient as the commercially available drug product “in the same, similar, or an easily substitutable strength,” or if the commercially available product can be used by the “same route of administration” (injection, for instance) prescribed for the commercially available products.
framing: assertive · carried by 1 article(s) · first seen 2026-10-07
🔮 The compounded drug represented significant cost savings—$250 a month versus the $399 a month she would have paid through LillyDirect, the direct-to-consumer site that people often use when their insurance doesn’t cover the drug.

Claims (132 extracted, 19 hedged)

Before the pandemic, Diane Kinkade lost weight with diet and exercise. asserted
Kinkade → lose → diet
But by 2026, she decided she needed to try something else. asserted
she → decide → something
She had prediabetes and high blood pressure, in addition to being overweight, but her doctor declined to prescribe her a GLP-1 weight-loss medication, saying he thought the side effects outweighed the benefits. asserted
effects → have → benefits
So she asked around and found a telehealth site that seemed more than happy to send her a prescription for a GLP-1 after a brief questionnaire. asserted
that → ask → questionnaire
But the telehealth site didn’t send her a brand-name drug. asserted
site → send → drug
It instead partnered with a compounding pharmacy to send her tirzepatide, the active ingredient in Eli Lilly’s popular drug Zepbound. asserted
It → partner → drug
The compounded drug represented significant cost savings—$250 a month versus the $399 a month she would have paid through LillyDirect, the direct-to-consumer site that people often use when their insurance doesn’t cover the drug. asserted
insurance → compound → drug
Kinkade, who is 72, says she wasn’t too worried about injecting herself with what the compounding pharmacy had sent, a combination of tirzepatide and vitamin B12. asserted
pharmacy → say → tirzepatide
At first, she started to lose weight. asserted
she → start → weight
But a few months into her injections, the telehealth site switched compounding pharmacies, and she had such bad side effects from the new medication (ordered with the same prescription) that she says she could barely function. uncertain
she → switch → prescription
Brain fog, nausea, diarrhea, and exhaustion all plagued her. asserted
fog → plague → her
“I could barely get up from the couch for a week,” she says. uncertain
she → get → week
She tried reaching out to the telehealth site for help, but they just sent her canned, AI-type responses, she says. asserted
she → try → responses
So she stopped taking the medication. asserted
she → stop → medication
If Eli Lilly had its way, patients seeking tirzepatide would not be able to receive anything but Zepbound, which is approved by the U.S. Food and Drug Administration (FDA). asserted
which → have → Administration
The company’s patent on the drug does not expire until 2036. asserted
patent → expire → 2036
In a 2024 news release from Eli Lilly about litigation it had pursued against compounding pharmacies, the company says that it is “the only lawful supplier of FDA-approved tirzepatide medicines in the United States” and that “patients taking a product referred to only as ‘tirzepatide’ are not taking an FDA-approved product.” asserted
patients → pursue → product
But because of a loophole—or a lack of enforcement, depending on who you ask—compounding pharmacies have still been sending patients compounded versions of tirzepatide. asserted
pharmacies → depend → tirzepatide
An estimated 5 million people are using compounded GLP-1s in the U.S., according to a Gallup poll released in July; of the 11% of U.S. adults taking GLP-1 medications for weight loss, nearly one in five uses compounding pharmacies. uncertain
five → estimate → pharmacies
Compounding pharmacies are set to boom even further because people may soon use them to get more peptides—short chains of amino acids that have become popular among influencers who tout their benefits (absent robust scientific evidence, in most cases) for a wide variety of ailments—than they previously could. uncertain
they → compound → ailments
In July, an FDA committee decided that compounding pharmacies should be allowed to prepare six peptides for consumers; the FDA has not yet decided whether it will adopt the recommendations. asserted
it → decide → recommendations
But compounding pharmacies are much less regulated than the drug manufacturers that make brand-name drugs. asserted
that → compound → drugs
As more telehealth sites prescribe these medications and pitch them as a way to lose weight while saving money, some patient advocates argue that more people like Kinkade will fall through the cracks of a broken regulatory system. asserted
people → prescribe → system
What are compounding pharmacies? asserted
pharmacies → compound → ?
Many pharmacies can compound medications. asserted
pharmacies → compound → medications
Compounding involves preparing a customized medication for a specific patient’s needs. asserted
Compounding → involve → needs
“Compounding is absolutely essential,” says Dr. Anjali Deshmukh, a pediatrician and law professor at Seton Hall University. asserted
Deshmukh → say → University
Deshmukh uses compounding pharmacies when, for example, she treats a 3-year-old with a serious disease who can’t swallow tablets and needs medication in a different form. asserted
who → use → form
For much of U.S. history, pharmacists had to mix individual medicines themselves: in the 1930s, three-quarters of prescriptions required in-pharmacy compounding. asserted
quarters → have → compounding
In this sense, compounding pharmacies have existed for as long as pharmacies have. asserted
pharmacies → compound → sense
For decades, pharmacies that compound small amounts of medication have operated under what’s called Section 503A of the Federal Food, Drug, and Cosmetic Act. asserted
what → compound → Act
Called 503As for short, they’re regulated by state boards of pharmacy. asserted
they → call → pharmacy
Because they dispense small amounts of medications for individual patients, only with a doctor’s prescription, most 503As aren’t subject to certain FDA rules that apply to traditional larger drug manufacturers. asserted
that → dispense → manufacturers
That includes what’s called “current good manufacturing practices,” which are regulatory standards that ensure drugmakers record and trace every batch of product they make and have their equipment tested regularly. asserted
equipment → include → product
They must adhere to other regulations, however. asserted
They → adhere → regulations
For instance, they must follow U.S. Pharmacopeia (USP) guidelines, which are set by a private non-profit that develops science-based standards for medicines, dietary supplements, and food ingredients. asserted
that → follow → medicines
And they must source their active ingredients from FDA-registered suppliers, says Scott Brunner, the chief executive officer of the Alliance for Pharmacy Compounding, a trade group. asserted
Brunner → source → Compounding
Struggles with regulation This regulatory system has broken down before. asserted
system → break → regulation
In 2012 a compounding pharmacy called the New England Compounding Center started mass-producing medications in a setting that had been flagged as unsanitary numerous times. asserted
that → compound → unsanitary
It shipped thousands of vials of contaminated steroid injections to patients. asserted
It → ship → patients
…and 92 more, not listed.
💬Give feedback
🕘History 🎫Support